首页> 外文期刊>eLife journal >The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy
【24h】

The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy

机译:DWORF微肽可在扩张型心肌病小鼠模型中增强收缩力并预防心力衰竭

获取原文
           

摘要

The heart is a muscular organ that contracts regularly to pump blood around the body, ensuring that nutrients and oxygen are carried to the cells and organs. Heart failure is a disease where the heart muscle becomes weakened, does not beat as strongly, and cannot pump blood as well as it should. Eventually, the heart can no longer deliver enough blood to meet the body’s needs. Although heart failure is a widespread disease, we still do not fully understand its underlying causes and the molecular machinery driving its progression. However, one common feature in many cases of heart failure is a problem with the supply of calcium to the heart muscle. Calcium is the molecule responsible for the process of muscle contraction; the strength of contraction depends on the amount of calcium available. Movement of calcium within heart cells is in turn controlled by an enzyme pump called SERCA. In 2016, researchers identified a small protein, DWORF, which increased the activity of SERCA. Makarewich et al. – including many of the researchers involved in the 2016 study – therefore wanted to find out more about how DWORF and SERCA worked together. They also wanted to test if DWORF could be used to boost the heart’s ability to pump blood efficiently, and if so, whether it could treat heart failure. Genetically modified mice that produced larger than normal amounts of DWORF had more available calcium in the heart muscle, which made it contract more strongly. This was true even when the same mice were treated with an excessive amount of a specific protein (phospholamban) that can lower the activity of SERCA, suggesting that DWORF might have a protective effect on the heart. Experiments using mice engineered to show symptoms of heart disease confirmed that DWORF treatment did indeed help their hearts beat normally, and, crucially, prevented them from developing heart failure. This work has shown for the first time that DWORF can restore the heart’s ability to pump normally in an experimental model of heart disease. In the future, Makarewich et al. hope that DWORF could be a useful target for new, more effective drugs to treat heart failure.
机译:心脏是一个肌肉器官,经常收缩以将血液泵送到身体周围,从而确保营养和氧气被带到细胞和器官。心力衰竭是一种疾病,在该疾病中,心肌会变得虚弱,无法正常跳动,无法正常抽血。最终,心脏无法再提供足够的血液来满足身体的需求。尽管心力衰竭是一种广泛的疾病,但我们仍未完全了解其根本原因以及推动其发展的分子机制。但是,在许多心力衰竭病例中,一个共同的特征是向心肌提供钙的问题。钙是负责肌肉收缩过程的分子。收缩的强度取决于可利用的钙量。钙在心脏细胞内的运动又由称为SERCA的酶泵控制。 2016年,研究人员发现了一种小的蛋白质DWORF,该蛋白质增加了SERCA的活性。 Makarewich等。 –包括许多参与2016年研究的研究人员–因此希望了解有关DWORF和SERCA如何一起工作的更多信息。他们还想测试DWORF是否可以用来增强心脏有效抽血的能力,如果可以,它是否可以治疗心力衰竭。产生大于正常DWORF量的转基因小鼠的心肌中有更多的可用钙,这使其收缩更强烈。即使对相同的小鼠用过量的可以降低SERCA活性的特定蛋白质(磷脂酰肌醇)治疗也是如此,这表明DWORF可能对心脏具有保护作用。使用经过设计可显示心脏病症状的小鼠进行的实验证实,DWORF治疗确实确实可以帮助他们的心脏正常跳动,并且至关重要的是,可以防止它们发展为心力衰竭。这项工作首次表明,DWORF可以在心脏病的实验模型中恢复心脏正常抽血的能力。将来,Makarewich等人。希望DWORF可以成为治疗心力衰竭的新型更有效药物的有用靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号